Skip to Content

'
Stefan Faderl

Present Title & Affiliation

Primary Appointment

Professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Clinical Interests

Dr. Faderl came to M.D. Anderson in 1996. Dr. Faderl graduated from Ludwig Maximilian Medical School in Munich, Germany in 1990 and received his medical/academic degree (magna cum laude) from the same institution in 1994. Dr. Faderl is board certified in Internal Medicine and Medical Oncology. He specializes in acute and chronic leukemias. His main areas of interest include acute lymphoblastic leukemias (ALL), acute myeloid leukemias (AML), chronic lymphocytic leukemia (CLL) and its variants, as well as chronic myeloid leukemias (CML). Dr. Faderl has authored and co-authored many abstracts, articles in peer-reviewed journals and book chapters. He serves on numerous editorial boards and is a member of several professional societies such as the American Society of Hematology (ASH), the American College of Physicians (ACP), and the American Society of Clinical Oncology. Contact information for Dr. Faderl is: (713) 745-4613 e-mail: sfaderl@mdanderson.org.

Education & Training

Degree-Granting Education

1990 Ludwig-Maximilians University Medical School, Munich, Germany, MD

Board Certifications

1/2019 Medical Oncology
1/2016 American Board of Internal Medicine

Experience/Service

Academic Appointments

Associate Professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 9/2005-8/2011

Institutional Committee Activities

Member, Institutional Review Board, 9/2008-present

Selected Publications

Peer-Reviewed Original Research Articles
1. Becker PS, Kantarjian HM, Appelbaum FR, Storer B, Pierce S, Shan J, Faderl S, Estey EH. Retrospective comparison of clofarabine versus fludarabine in combination with high dose cytarabine with or without granulocyte colony-stimulating factor as salvage therapies for acute myeloid leukemia. Haematologica 98(1):114-8, 1/2013. e-Pub 7/16/2012. PMCID: PMC3533672.
2. Quintás-Cardama A, Ravandi F, Liu-Dumlao T, Brandt M, Faderl S, Pierce S, Borthakur G, Garcia-Manero G, Cortes J, Kantarjian H. Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemia. Blood 120(24):4840-4845, 12/6/2012. e-Pub 10/15/2012. PMID: 23071272.
3. Kantarjian H, Faderl S, Garcia-Manero G, Luger S, Venugopal P, Maness L, Wetzler M, Coutre S, Stock W, Claxton D, Goldberg SL, Arellano M, Strickland SA, Seiter K, Schiller G, Jabbour E, Chiao J, Plunkett W. Oral sapacitabine for the treatment of acute myeloid leukaemia in elderly patients: a randomised phase 2 study. Lancet Oncol 13(11):1096-1104, 11/2012. e-Pub 10/2012. PMID: 23075701.
4. Faderl S, Ravandi F, Huang X, Wang X, Jabbour E, Garcia-Manero G, Kadia T, Ferrajoli A, Konopleva M, Borthakur G, Burger J, Feliu J, Kantarjian HM. Clofarabine plus low-dose cytarabine followed by clofarabine plus low-dose cytarabine alternating with decitabine in acute myeloid leukemia frontline therapy for older patients. Cancer 118(18):4471-4477, 9/2012. e-Pub 1/2012. PMID: 22282348.
5. Tong WG, Quintás-Cardama A, Kadia T, Borthakur G, Jabbour E, Ravandi F, Faderl S, Wierda W, Pierce S, Shan J, Bueso-Ramos C, Kantarjian H, Garcia-Manero G. Predicting survival of patients with hypocellular myelodysplastic syndrome: Development of a disease-specific prognostic score system. Cancer 118(18):4462-4470, 9/2012. e-Pub 1/2012. PMID: 22252728.
6. Nazha A, Cortes J, Faderl S, Pierce S, Daver N, Kadia T, Borthakur G, Luthra R, Kantarjian H, Ravandi F. Activating mutations of the FMS-like tyrosine kinase-3 internaltandem duplication (FLT3-ITD) at complete response and relapsein patients with acute myeloid leukemia. Haematologica 97(8):1242-1245, 8/2012. e-Pub 4/2012. PMCID: PMC3409823.
7. Jabbour E, Garcia-Manero G, Cortes J, Ravandi F, Plunkett W, Gandhi V, Faderl S, O'Brien S, Borthakur G, Kadia T, Burger J, Konopleva M, Brandt M, Huang X, Kantarjian H. Twice-Daily Fludarabine and Cytarabine Combination With or Without Gentuzumab Ozogamicin is Effective in Patients With Relapsed/Refractory Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, and Blast- Phase Chronic Myeloid Leukemia. Clin Lymphoma Myeloma Leuk 12(4):244-251, 8/2012. e-Pub 4/2012. PMID: 22534616.
8. Faderl S, Wetzler M, Rizzieri D, Schiller G, Jagasia M, Stuart R, Ganguly S, Avigan D, Craig M, Collins R, Maris M, Kovacsovics T, Goldberg S, Seiter K, Hari P, Greiner J, Vey N, Recher C, Ravandi F, Wang ES, Vasconcelles M, Huebner D, Kantarjian HM. Clofarabine Plus Cytarabine Compared With Cytarabine Alone in Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia: Results From the CLASSIC I Trial. J Clin Oncol 30(20):2492-9, 7/10/2012. e-Pub 5/14/2012. PMID: 22585697.
9. Eghtedar A, Verstovsek S, Estrov Z, Burger J, Cortes J, Bivins C, Faderl S, Ferrajoli A, Borthakur G, George S, Scherle PA, Newton RC, Kantarjian HM, Ravandi F. Phase II study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including post myeloproliferative neoplasms (MPN) acute myeloid leukemia (AML). Blood 119(20):4614-8, 5/2012. e-Pub 3/2012. PMID: 22422826.
10. Ravandi F, Patel K, Luthra R, Faderl S, Konopleva M, Kadia T, Brandt M, Pierce S, Kornblau S, Andreeff M, Wang X, Garcia-Manero G, Cortes J, Kantarjian H. Prognostic significance of alterations in IDH enzyme isoforms in patients with AML treated with high-dose cytarabine and idarubicin. Cancer 118(10):2665-73, 5/2012. e-Pub 10/2011. PMID: 22020636.
11. Kantarjian H, Thomas D, Jorgensen J, Jabbour E, Kebriaei P, Rytting M, York S, Ravandi F, Kwari M, Faderl S, Rios MB, Cortes J, Fayad L, Tarnai R, Wang SA, Champlin R, Advani A, O'Brien S. Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study. Lancet Oncol 13(4):403-11, 4/2012. e-Pub 2/21/2012. PMID: 22357140.
12. Schanz J, Tüchler H, Solé F, Mallo M, Luño E, Cervera J, Granada I, Hildebrandt B, Slovak ML, Ohyashiki K, Steidl C, Fonatsch C, Pfeilstöcker M, Nösslinger T, Valent P, Giagounidis A, Aul C, Lübbert M, Stauder R, Krieger O, Garcia-Manero G, Faderl S, Pierce S, Le Beau MM, Bennett JM, Greenberg P, Germing U, Haase D. New Comprehensive Cytogenetic Scoring System for Primary Myelodysplastic Syndromes (MDS) and Oligoblastic Acute Myeloid Leukemia After MDS Derived From an International Database Merge. J Clin Oncol 30(8):820-9, 3/2012. e-Pub 2/2012. PMID: 22331955.
13. Shihadeh F, Reed V, Faderl S, Medeiros LJ, Mazloom A, Hadziahmetovic M, Kantarjian H, Allen P, Ballas L, Pierce S, Dabaja B. Cytogenetic profile of patients with acute myeloid leukemia and central nervous system disease. Cancer 118(1):112-117, 1/2012. e-Pub 6/2011. PMID: 21692072.
14. Faderl S, Garcia-Manero G, Jabbour E, Ravandi F, Borthakur G, Estrov Z, Gandhi V, Byrd AL, Kwari M, Cortes J, Kantarjian HM. A randomized study of 2 dose levels of intravenous clofarabine in the treatment of patients with higher-risk myelodysplastic syndrome. Cancer 118(3):722-728, 2012. e-Pub 7/2011. PMID: 21751197.
15. Becker PS, Kantarjian HM, Appelbaum FR, Petersdorf SH, Storer B, Pierce S, Shan J, Hendrie PC, Pagel JM, Shustov AR, Stirewalt DL, Faderl S, Harrington E, Estey EH. Clofarabine with high dose cytarabine and granulocyte colony-stimulating factor (G-CSF) priming for relapsed and refractory acute myeloid leukaemia. Br J Haematol 155(2):182-189, 10/2011. e-Pub 8/2011. PMID: 21848522.
16. Naqvi K, Jabbour E, Bueso-Ramos C, Pierce S, Borthakur G, Estrov Z, Ravandi F, Faderl S, Kantarjian H, Garcia-Manero G. Implications of discrepancy in morphological diagnosis of myelodysplastic syndrome between referral and tertiary care centers. Blood 118(17):4690-3, 10/2011. e-Pub 8/2011. PMID: 21868570.
17. Faderl S, Bueso-Ramos C, Liu Z, Pal A, Bornmann W, Ciurea DV, Harris D, Hazan-Halevy I, Kantarjian HM, Estrov Z. Kit inhibitor APcK110 extends survival in an AML xenograft mouse model. Invest New Drugs 29(5):1094-7, 10/2011. e-Pub 6/2010. PMID: 20517635.
18. Ravandi F, O'Brien S, Jorgensen J, Pierce S, Faderl S, Ferrajoli A, Koller C, Challagundla P, York S, Brandt M, Luthra R, Burger J, Thomas D, Keating M, Kantarjian H. Phase II study of cladribine followed by rituximab in patients with hairy cell leukemia. Blood 118(14):3818-3823, 10/2011. e-Pub 8/2011. PMID: 21821712.
19. Badoux XC, Keating MJ, Wang X, O'Brien SM, Ferrajoli A, Faderl S, Burger J, Koller C, Lerner S, Kantarjian H, Wierda WG. Cyclophosphamide, fludarabine, rituximab and alemtuzumab (CFAR) as salvage therapy for heavily pre-treated patients with chronic lymphocytic leukemia. Blood 118(8):2085-93, 8/2011. e-Pub 6/2011. PMID: 21670470.
20. Parikh SA, Keating MJ, O'Brien S, Wang X, Ferrajoli A, Faderl S, Burger J, Koller C, Estrov Z, Badoux X, Lerner S, Wierda WG. Frontline chemoimmunotherapy with fludarabine, cyclophosphamide, alemtuzumab, and rituximab (CFAR) for high-risk chronic lymphocytic leukemia. Blood 118(8):2062-2068, 8/2011. e-Pub 7/2011. PMID: 21750315.
21. Kantarjian H, O'Brien S, Jabbour E, Shan J, Ravandi F, Kadia T, Faderl S, Garcia-Manero G, Borthakur G, Cortes J. Impact of Treatment End Point Definitions on Perceived Differences in Long-Term Outcome With Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukemia. J Clin Oncol 29(23):3173-3178, 8/2011. e-Pub 7/2011. PMID: 21747082.
22. Al-Kali A, Cortes J, Faderl S, Jones D, Abril C, Pierce S, Brandt M, Kantarjian H, Ravandi F. Patterns of Molecular Response to and Relapse After Combination of Sorafenib, Idarubicin, and Cytarabine in Patients With FLT3 Mutant Acute Myeloid Leukemia. Clin Lymphoma Myeloma Leuk 11(4):361-366, 8/2011. PMID: 21816375.
23. Chen Y, Cortes J, Estrov Z, Faderl S, Qiao W, Abruzzo L, Garcia-Manero G, Pierce S, Huang X, Kebriaei P, Kadia T, De Lima M, Kantarjian H, Ravandi F. Persistence of Cytogenetic Abnormalities at Complete Remission After Induction in Patients With Acute Myeloid Leukemia: Prognostic Significance and the Potential Role of Allogeneic Stem-Cell Transplantation. J Clin Oncol 29(18):2507-13, 6/2011. e-Pub 5/2011. PMID: 21555694.
24. Badoux XC, Keating MJ, Wang X, O'Brien SM, Ferrajoli A, Faderl S, Burger J, Koller C, Lerner S, Kantarjian H, Wierda WG. Fludarabine, cyclophosphamide and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLL. Blood 117(11):3016-24, 3/2011. e-Pub 1/2011. PMID: 21245487.
25. Faderl S, Thomas DA, O'Brien S, Ravandi F, Garcia-Manero G, Borthakur G, Ferrajoli A, Verstovsek S, Ayoubi M, Rytting M, Feliu J, Kantarjian HM. Augmented Hyper-CVAD Based on Dose-Intensified Vincristine, Dexamethasone, and Asparaginase in Adult Acute Lymphoblastic Leukemia Salvage Therapy. Clin Lymphoma Myeloma Leuk 11(1):54-9, 2/2011. PMID: 21454191.
26. Thomas D, O'Brien S, Faderl S, Ravandi F, Jabbour E, Pierce S, Cortes J, Kantarjian H. Anthracycline dose intensification in adult acute lymphoblastic leukemia: lack of benefit in the context of the fractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimen. Cancer 116(19):4580-4589, 10/2010. e-Pub 6/2010. PMID: 20572037.
27. Faderl S, Garcia-Manero G, Estrov Z, Ravandi F, Borthakur G, Cortes JE, O'Brien S, Gandhi V, Plunkett W, Byrd A, Kwari M, Kantarjian HM. Oral clofarabine in the treatment of patients with higher-risk myelodysplastic syndrome. J Clin Oncol 28(16):2755-2760, 6/2010. e-Pub 4/2010. PMID: 20421540.
28. Faderl S, Ferrajoli A, Wierda W, O'Brien S, Lerner S, Keating MJ. Alemtuzumab by continuous intravenous infusion followed by subcutaneous injection plus rituximab in the treatment of patients with chronic lymphocytic leukemia recurrence. Cancer 116(10). e-Pub 3/2010. PMID: 20225334.
29. Faderl S, O'Brien S, Pui C-H, Stock W, Wetzler M, Hoelzer D, Kantarjian H. Adult acute lymphoblastic leukemia - concepts and strategies. Cancer 116(5):1165-1176, 2010. PMID: 20101737.
30. Faderl S, Wierda W, O'Brien S, Ferrajoli A, Lerner S, Keating MJ. Fludarabine, cyclophosphamide, mitoxantrone plus rituximab (FCM-R) in frontline CLL <70 years. Leuk Res 34(3):284-288, 2010. PMID: 19646755.
31. Faderl S, Ferrajoli A, Frankfurt O, Pettitt A. Treatment of B-cell chronic lymphocytic leukemia with nonchemotherapeutic agents: experience with single-agent and combination therapy. Leukemia 23(3):457-466, 5/2009. PMID: 18987653.
32. Faderl S. Last exit clofarabine? Leuk Lymphoma 50(12):1907-1908, 2009. PMID: 20001243.
33. Kantarjian H, Garcia-Manero G, O'Brien S, Faderl S, Ravandi F, Westwood R, Green SR, Chiao JH, Boone PA, Cortes J, Plunkett W. Phase I clinical and pharmacokinetic study of oral sapacitabine in patients with acute leukemia and myelodysplastic syndrome. J Clin Oncol 28(2):285-291, 2009. PMID: 19933907.
34. Garg RJ, Kantarjian H, O'Brien S, Quintas-Cardama A, Faderl S, Estrov Z, Cortes J. The use of nilotinib or dasatinib after failure to two prior tyrosine kinase inhibitors (TKI): long-term follow-up. Blood 114(20):4361-4368, 2009. PMID: 19729517.
35. Faderl S, Ravandi F, Huang X, Garcia-Manero G, Ferrajoli A, Estrov Z, Borthakur G, Verstovsek S, Thomas DA, Kwari M, Kantarjian HM. A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as frontline therapy for patients age >= 60 years with acute myeloid leukemia and high-risk myelodysplastic syndrome. Blood 112(5):1638-1645, 3/2008. PMID: 18565853.
36. Faderl S, Ferrajoli A, Wierda W, Huang X, Verstovsek S, Ravandi F, Estrov Z, Borthakur G, Kwari M, Kantarjian HM. Clofarabine combinations as acute myeloid leukemia salvage therapy. Cancer 113(8):2090-2096, 2008. PMID: 18756533.
37. Faderl S, Ferrajoli A, Harris D, Van Q, Kantarjian HM, Estrov Z. Atiprimod blocks phosphorylation of JAK-STAT and inhibits proliferation of acute myeloid leukemia (AML) cells. Leuk Res 31:91-5, 1/2007. PMID: 16828865.
38. Faderl S, Rai K, Gribben J, Byrd JC, Flinn IW, O'Brien S, Sheng S, Esseltine DL, Keating MJ. Phase II study of single-agent bortezomib for the treatment of patients with fludarabine-refractory B-cell chronic lymphocytic leukemia. Cancer 107(5):916-24, 9/2006. PMID: 16832816.
Other Articles
1. Ferrajoli A, O'Brien SM, Faderl S, Wierda WG, Reuben JM, Keating MJ. Lenalidomide: An emerging option in chronic lymphocytic leukemia. Haemagologica Meeting Reports 3(3):103-105, 2009.

Last updated: 3/5/2013